Biography

Sutha Satkunarajah is Vice President, Strategy and Operations at Flagship Pioneering UK, the UK office of the $14bn life sciences venture creation firm behind Moderna, Generate Biomedicines and more than 100 platform companies. As one of Flagship’s first hires outside the US, Sutha has helped build the London hub — Flagship’s first base in Europe —  driving its UK ecosystem partnerships. These include Flagship’s global R&D collaboration with Cambridge University Health Partners, Wellcome Sanger Institute and the Milner Therapeutics Institute, its strategic partnership and co-location with the Francis Crick Institute, and emerging links with the UK’s regulatory and translational research infrastructure. Sutha also served as Senior Director of Preemptive Health and Medicine at Flagship, working on the next generation of platforms that predict, detect and intervene upstream of disease. 

Before Flagship, Sutha served as an Innovation Fellow and Advisor to Lord Darzi at Imperial’s Institute of Global Health Innovation, where he co-led the Programme Management Office for REACT, the UK’s largest COVID-19 community surveillance study. Earlier in his career he led the analytics for Lord Darzi’s 2018 review of Health and Care in England, which underpinned the case for an additional £20bn of annual NHS funding. He brings additional experience from private equity (HgCapital), management consulting (Carnall Farrar, L.E.K., Oliver Wyman) and industry (Bupa). He is a regular speaker at international life sciences forums including most recently at HLTH Europe. 

Sutha is a member of the UK Biobank Industry Advisory Board and the Knowledge Quarter Steering Group and serves as a Governor of Tiffin School. He graduated from Harvard College.